These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 9729027

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Tackling the real culprits in Crohn's disease.
    Bonn D.
    Lancet; 1998 Jun 06; 351(9117):1710. PubMed ID: 9734899
    [No Abstract] [Full Text] [Related]

  • 4. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease.
    Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, Tami JA, Bennett CF, Kisner DL, Shanahan WR.
    Gastroenterology; 1998 Jun 06; 114(6):1133-42. PubMed ID: 9609749
    [Abstract] [Full Text] [Related]

  • 5. Antisense oligonucleotides in lung cancer.
    Pujol JL, Jacot W.
    Suppl Tumori; 2002 Jun 06; 1(4):S50-1. PubMed ID: 12415820
    [No Abstract] [Full Text] [Related]

  • 6. The clinical experience of antisense therapy to ICAM-1 in Crohn's disease.
    Yacyshyn B, Bowen-Yacyshyn MB, Shanahan W.
    Curr Opin Mol Ther; 1999 Jun 06; 1(3):332-5. PubMed ID: 11713798
    [Abstract] [Full Text] [Related]

  • 7. Gene polymorphisms and serological markers of patients with active Crohn's disease in a clinical trial of antisense to ICAM-1.
    Yacyshyn BR, Schievella A, Sewell KL, Tami JA.
    Clin Exp Immunol; 2005 Jul 06; 141(1):141-7. PubMed ID: 15958080
    [Abstract] [Full Text] [Related]

  • 8. Antisense oligonucleotide treatment of inflammatory bowel diseases.
    Yacyshyn BR.
    Methods Mol Med; 2005 Jul 06; 106():295-305. PubMed ID: 15375323
    [No Abstract] [Full Text] [Related]

  • 9. Antisense oligonucleotides: an evolving technology for the modulation of gene expression in human disease.
    Green DW, Roh H, Pippin J, Drebin JA.
    J Am Coll Surg; 2000 Jul 06; 191(1):93-105. PubMed ID: 10898188
    [No Abstract] [Full Text] [Related]

  • 10. A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease.
    Yacyshyn B, Chey WY, Wedel MK, Yu RZ, Paul D, Chuang E.
    Clin Gastroenterol Hepatol; 2007 Feb 06; 5(2):215-20. PubMed ID: 17296530
    [Abstract] [Full Text] [Related]

  • 11. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease.
    Schreiber S, Nikolaus S, Malchow H, Kruis W, Lochs H, Raedler A, Hahn EG, Krummenerl T, Steinmann G, German ICAM-1 Study Group.
    Gastroenterology; 2001 May 06; 120(6):1339-46. PubMed ID: 11313303
    [Abstract] [Full Text] [Related]

  • 12. Genetic therapy for transplant vascular sclerosis.
    Bennett CF, Stepkowski SM.
    Transpl Immunol; 1997 Dec 06; 5(4):299-302. PubMed ID: 9504151
    [No Abstract] [Full Text] [Related]

  • 13. GEM 91--an antisense oligonucleotide phosphorothioate as a therapeutic agent for AIDS.
    Agrawal S, Tang JY.
    Antisense Res Dev; 1992 Dec 06; 2(4):261-6. PubMed ID: 1363378
    [No Abstract] [Full Text] [Related]

  • 14. Antisense therapy in oncology: new hope for an old idea?
    Tamm I, Dörken B, Hartmann G.
    Lancet; 2001 Aug 11; 358(9280):489-97. PubMed ID: 11513935
    [Abstract] [Full Text] [Related]

  • 15. Technology evaluation: ISIS-104838, OraSense.
    Kennewell P.
    Curr Opin Mol Ther; 2003 Feb 11; 5(1):76-80. PubMed ID: 12669475
    [Abstract] [Full Text] [Related]

  • 16. Alicaforsen. Isis Pharmaceuticals.
    Gewirtz AT, Sitaraman S.
    Curr Opin Investig Drugs; 2001 Oct 11; 2(10):1401-6. PubMed ID: 11890355
    [Abstract] [Full Text] [Related]

  • 17. Significant inhibitory effects of Hybridon's antisense compound on various HIV-1 replication steps in in vitro tests.
    AIDS Patient Care STDS; 1996 Dec 11; 10(6):375-6. PubMed ID: 11361558
    [No Abstract] [Full Text] [Related]

  • 18. Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.
    Holmlund JT, Monia BP, Kwoh TJ, Dorr FA.
    Curr Opin Mol Ther; 1999 Jun 11; 1(3):372-85. PubMed ID: 11713802
    [Abstract] [Full Text] [Related]

  • 19. Still looking for the real GEM.
    GMHC Treat Issues; 1996 Apr 11; 10(4):9. PubMed ID: 11363711
    [Abstract] [Full Text] [Related]

  • 20. Technology evaluation: alicaforsen (Isis).
    Gewirtz AT, Sitaraman SV.
    Curr Opin Mol Ther; 2005 Jun 11; 7(3):273-81. PubMed ID: 15977426
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.